OpenAI acquires a16z-backed Orchestra Bio to build life sciences agents
julesyoo · x · 2026-10-21
OpenAI has acquired Orchestra Bio, an a16z portfolio company. The team will join OpenAI to build agent applications for life sciences, aiming to accelerate biopharma's journey from scientific discovery to novel medicines. The deal was confirmed by a16z partners Jorge Conde and Jay Rughani.
Related event: OpenAI Acquires Orchestra Bio to Push AI Agents into Drug Development(13 posts)→
More from Companies & People
- NJIT's top research honor goes to HPC pioneer David Bader — Prof_DavidBader · 2026-10-21
- Cloudflare's first Cold Start contest: Haelo Health wins $500k, Polylane takes $100k — threepointone · 2026-10-21
- Together AI hiring PhD research interns for summer 2027 on text and speech agents — coryshain · 2026-10-21
- Spotify removed 50M+ AI slop tracks from recommendations in a year to back human artists — moustaki · 2026-10-21
- Mistral CEO Arthur Mensch on European AI sovereignty, gigawatt-scale infra and AGI risk — beffjezos · 2026-10-21
- Sundar Pichai to appear on Alex Heath's Sources podcast tomorrow — gaganghotra_ · 2026-10-21